Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population

Pharmacogenetics and Genomics

Volumn 18, Issue 12, 2008, Pages 1095-1102

  Conrad, Douglas J ^a,d   Stenbit, Antine E ^e   Zettner, Erika M ^b   Wick, Ivan ^c   Eckhardt, Colleen ^c   Hardiman, Gary ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aminoglycoside; Audiologic testing; Cystic flbrosis; Mitochondrial 12S ribosomal RNA; Mitochondrial genome; Ototoxicity

Indexed keywords

AZITHROMYCIN; COLISTIN; GENOMIC DNA; GENTAMICIN; MITOCHONDRIAL RNA; RNA 12S; TOBRAMYCIN;

ADULT; ARTICLE; CYSTIC FIBROSIS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEARING LOSS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE;

ADULT; AUDIOMETRY, PURE-TONE; BASE SEQUENCE; CONSERVED SEQUENCE; CYSTIC FIBROSIS; DEMOGRAPHY; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; MUTATION; RNA, RIBOSOMAL; TRANSCRIPTION FACTORS;

NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 57149134391     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328312b072     Document Type: Article

References (35)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-951.
2. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002; 54:1359-1371.
3. Quinton PM. The neglected ion: HCO3. Nat Med 2001; 7:292-293.
4. Foundation CF. Patient Registry 2004 Annual Report, Bethesday, Maryland, 2004.
5. Sande MA, Mandell GL.'Antimicrobial agents: tetracyclines, chloramphenicol, erthromycin, and miscellaneous antibacterial agents'. In: Oilman A, Rail A, Nies A, Taylor A, editors. Goodman and Oilman's, The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. pp. 1117-1145.
6. Katbamna B, Homnick DN, Marks JH. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. Eur Hear 1999; 20:393-402.
7. Usami S, Abe S, Shinkawa H, Kimberling WJ. Sensorineural hearing loss caused by mitochondrial DNA mutations: special reference to the 1555A>G mutation. J Commun Disord 1998; 31:423-434; quiz 434-435.
8. Fischel-Ghodsian N. Mitochondrial genetics and hearing loss: the missing link between genotype and phenotype. Proc Soc Exp Biol Med 1998; 218:1-6.
9. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci 1999; 884:99-109.
10. Prezant TR, Agapian JV, Bohlman MC, Bu X, Oztas S, Qiu WQ, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4:289-294.
11. Fischel-Ghodsian N, Kopke RD, Ge X. Mitochondrial dysfunction in hearing loss. Mitochondrion 2004; 4:675-694.
12. Zhao H, Li R, Wang Q, Van Q, Deng JH, Han D, et al. Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel 1494C>T mutation in the MT-RNR1 gene in a large Chinese family. Am J Hum Genet 2004; 74:139-152.
13. Li Z, Li R, Chen J, Liao Z, Zhu Y, Qian Y, et al. Mutational analysis of the MT-RNR1 gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. Hum Genet 2005; 117: 9-15.
14. MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org, 2007.
15. Bykhovskaya Y, Estivill X, Taylor K, Hang T, Hamon M, Casano RA, et al. Candidate locus for a nuclear modifier gene for maternally inherited deafness. Am J Hum Genet 2000; 66:1905-1910.
16. Bykhovskaya Y, Mengesha E, Wang D, Yang H, Estivill X, Shohat M, et al. Phenotype of non-syndromic deafness associated with the mitochondrial 1555A>G mutation is modulated by mitochondrial RNA modifying enzymes MTO1 and GTPBP3. Mol Genet Metab 2004; 83:199-206.
17. Carhart R, Jerger JJ. Preferred method for clinical determination of pure-tone thresholds. J Speech Hearing Disorders 1959; 24:330-345.
18. American National Standards Institute. American national standard criteria for permissible ambient noise during audiometric testing (ANSI S3. 1-1071). New York; 1971.
19. Thompson JD, Higgins DG, Gibson TJ. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
20. Guan MX. Molecular pathogenetic mechanism of maternally inherited deafness. Ann N Y Acad Sci 2004; 1011:259-271.
21. Fischel-Ghodsian N. Mitochondrial mutations and hearing loss: paradigm for mitochondrial genetics. Am J Hum Genet 1998; 62:15-19.
22. Casano RA, Bykhovskaya Y, Johnson DF, Hamon M, Torricelli F, Bigozzi M, et al. Hearing loss due to the mitochondrial 1555A>G mutation in Italian families. Am J Med Genet 1998; 79:388-391.
23. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000; 9:1787-1793.
24. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 2007; 15:352-357.
25. Cheng AG, Cunningham LL, Rubel EW. Mechanisms of hair cell death and protection. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 343-348.
26. Roland PS. New developments in our understanding of ototoxicity. Ear, Nose and Throat J 2004; 83:15-16; discussion 16-17.
27. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, Wendt KA, Nelson RA, Arnos KS, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997; 18:173-178.
28. Usami S, Abe S, Akita J, Shinkawa H, Kimberling WJ. Sensorineural hearing loss associated with the mitochondrial mutations. Adv Otorhinolaryngol 2000; 56:203-211.
29. Scrimshaw BJ, Faed JM, Tate WP, Yun K. Rapid identification of an 1555A>G mutation in human mitochondrial DNA implicated in aminoglycoside-induced ototoxicity. J Hum Genet 1999; 44:388-390.
30. Tang HY, Hutcheson E, Neill S, Drummond-Borg M, Speer M, Alford RL. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? Genet Med 2002; 4:336-345.
31. Hernstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, Anderson C, et al. Reduced median network analysis of complete mitochondrial DNA coding region sequences for the major African, Asian and European Haplogroups. Am J Hum Genet 2002; 70:1152-1171.
32. Wang Q, Li QZ, Han D, Zhao Y, Zhao L, Qian Y, et al. Clinical and molecular analysis of a four-generation Chinese family with amino-glycoside- induced and nonsyndromic hearing lose associated with the MT-RNR1 1494C>T mutation. Biochem Biophys Res Commun 2006; 340:583-588.
33. Bacino C, Prezant TR, Bu X, Foumier P, Fiachel-Ghodsian N. Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness. Pharmacogenetics 1995; 8:165-172.
34. Casano RA, Johnson DF, Bykhovskaya Y, Torricelli F, Bigoizi M, Fischel-Ghodsian N. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999; 20:151-156.
35. Kobayashi K, Oguchi T, Asamura K, Miyagawa M, Horai S, Abe S, et al. Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. Auris Nasus Larynx 2006; 32:119-124.